Back to Search Start Over

Rituximab-supplemented high-dose sequential chemotherapy (HDS) has superior response rate and event-free survival (EFS) compared to R-CHOP in poor risk follicular lymphoma (FL) at diagnosis: Results from a multicenter randomized GITMO trial

Authors :
Ladetto, M
Ricca, I
Benedetti, F
Vitolo, U
Patti, C
Rambaldi, A
Liberati, Anna Marina
All, Et
Publication Year :
2005

Details

Database :
OpenAIRE
Accession number :
edsair.od......3982..ca7507f6f9c766c7a89e012de5875602

Tools

Authors Abstract Subjects Details